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The purpose of this study was to investigate associations between combinations of body mass index (BMI) cate-
gories plus non-alcoholic fatty liver disease (NAFLD) and diabetes mellitus (DM) among Korean adults. We 
prepared the data of 5665 subjects aged 20 years and over who had visited a health promotion center. We ex-
cluded 582 subjects as they had a viral or alcoholic liver disease. According to BMI-NAFLD status, the subjects 
were categorized as non-obese (BMI<25 kg/m2) without NAFLD (n=2568), obese (BMI≥25 kg/m2) without 
NAFLD (n=572), non-obese with NAFLD (n=748), or obese with NAFLD (n=1195). The prevalence of NAFLD 
was highest in the obese subjects with DM (87.9%). In non-obese and non-DM subjects, the prevalence of 
NAFLD was lowest (18.4%). After adjustment of age, gender, waist circumference, smoking status, alcohol 
drinking, regular exercise, the odd ratios for DM or DM plus impaired fasting glucose (IFG) of subjects with 
mild NAFLD regardless of obesity were almost 2-fold compared to non-obese subjects without NAFLD. More-
over, those of subjects with moderate or severe NAFLD regardless of obesity were about 4- fold. Clinicians and 
investigators need to pay attention to non-obese patients with fatty liver. 
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INTRODUCTION 
Diabetes mellitus (DM) is diagnosed and characterized by 
chronic hyperglycemia.1 The effects of DM include long-
term damage, dysfunction, and failure of various organs, 
especially the eyes, kidneys, heart, and blood vessels.2 
The incidence of DM is increasing rapidly worldwide, with 
the economic burden of diabetes caused by increased 
health resource use and lost productivity increase rapidly.3 
Non-alcoholic steatohepatitis (NASH) was first de-
scribed by Ludwig et al.4 about 30 years ago and is now 
considered part of a spectrum of non-alcoholic fatty liver 
diseases (NAFLD). Epidemiological studies have docu-
mented that NAFLD is independently associated with 
obesity, hypertriglyceridemia, low HDL-cholesterol, insu-
lin resistance.5-8 Patients with NAFLD have an increased 
risk of developing not only liver but also cardiovascular 
morbidity. 
Once the liver is fatty, the action of insulin to inhibit 
hepatic glucose production is impaired, which results in 
hyperglycemia and hyperinsulinemia.9 Although the pre-
valence of DM increased in obesity,10 not all obese subjects 
are going to be DM patients. Furthermore, insulin resis-
tance can be found even in lean individuals.11 NAFLD is 
considered to be an important predisposing step in obese 
individuals towards the development of diabetes.12 
However, in the cases of non-obese patients with fatty 
liver or obese patients without fatty liver, the relationship 
between their health status and DM is quite unknown. 
The purpose of this study was to examine the prevalence 
of NAFLD in both non-obese and obese people according 
to DM classification and to investigate associations be-
tween combinations of body mass index categories plus 
NAFLD and DM among Korean adults. 
 
MATERIALS AND METHODS 
Subjects  
We prepared the data of 5665 subjects aged 20 years and 
over who had visited a health promotion center from Jan-
uary 2006 and December 2007. Subjects were subse-
quently divided into groups of normal glucose (NG), im-
paired fasting glucose (IFG), and DM.13 Subjects with 
normal fasting glucose had values below 100 mg/dL. Ac-
cording to the American Diabetes Association guidelines,14 
subjects with IFG were defined by fasting glucose values 
of 100 to 125 mg/dL. Subjects with DM were defined by 
fasting glucose above 126 mg/dL or by taking any hypo-
glycemic agents including insulin. 
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We excluded subjects from the analysis if they had a 
daily alcohol consumption of more than 2 drinks (alcohol 
use ≥30 g/day) for men or more than 1.5 drinks (alcohol 
use ≥20 g/day) for women. We also excluded subjects 
who were positive for the hepatitis B surface antigen or 
hepatitis C virus antibody. Subjects who had a medical 
history of chronic liver disease or liver cirrhosis, as well 
as those taking current medications for liver disease were 
also excluded from the study. The final study population 
consisted of 5083 subjects (2552 men and 2531 women).  
The institutional review board of the Myongji Hospital 
approved this study. 
 
Measurements 
During subjects’ health promotion center visits, medical 
history and life-style-related data (alcohol consumption, 
smoking, and exercise status) were collected via a ques-
tionnaire and history taking. Current medication use was 
verified by an examination of prescriptions. A smoking 
habit was defined as currently smoking cigarettes. Alco-
hol consumption was measured according to the amount 
of alcohol more than one bottle of soju (a kind of distilled 
spirits containing 56.8 g of pure alcohol) consumed per 
week. Regular exercise was defined as 30 min or more at 
a time, three times per week regularly. 
Body weight was measured to the nearest 0.1 kg using 
an electronic scale. Height was measured to the nearest 
0.1 cm using a stadiometer. Body mass index (BMI) was 
calculated as weight/height2 (kg/m2). Obesity was defined 
as BMI over 25 according to Western Pacific Region of 
 
 
Table 1. Clinical and metabolic characteristics of subjects 
 
NG† IFG‡ DM§ 
Variables n=4072 n=675 n=336 
p-value 
Age (years) 45.8 ± 11.8 50.8 ± 10.5*      54.8 ± 9.4**,*** <0.001 
Gender (male), n (%) 1925(47.3) 423(62.7) 204(60.7) <0.001 
BMI ¶ (kg/m2) 23.5 ± 3.1 25.1 ± 3.0*   25.1 ± 2.9** <0.001 
Waist circumference (cm) 80.4 ± 9.3 85.9 ± 8.3*      87.3 ± 7.5**,*** <0.001 
Body fat (%) 25.8 ± 6.6 26.9 ± 6.5*   27.4 ± 6.8** <0.001 
Blood pressure (mmHg)     
Systolic 125.6 ± 16.4 134.8 ± 16.5*   135.0 ± 16.0** <0.001 
Diastolic 73.2 ± 10.7 78.9 ± 10.4*   78.3 ± 9.6** <0.001 
Current smoker, n (%) 841 (20.7) 149 (22.1) 77 (22.9) 0.470 
Alcohol drinking, n (%) 892 (21.9) 244 (36.2) 83 (24.7) <0.001 
Regular exercise, n (%) 1962 (48.2) 249 (36.9) 138 (41.1) <0.001 
HTN†† medication, n (%) 382 (9.4) 117 (17.3) 104 (31.0) <0.001 
Grade of fatty liver     
No (N=3140), n (%) 2782(88.6) 259(8.3) 99(3.2)  
Mild (N=1087), n (%) 800(73.6) 204(18.8) 83(7.6)  
Moderate (N=767), n (%) 445(58.0) 186(24.3) 136(17.7)  
Severe (N=89), n (%) 45(50.6) 26(29.2) 18(20.2) <0.001 
Fibrosis score -3.2±1.0 -2.0±1.0* -1.8±1.1† <0.001 
Fasting glucose (mg/dl) 86.4 ± 7.0 107.0 ± 6.4*      150.0 ± 43.9**,*** <0.001 
Fasting insulin†††\ (uIU/L) 5.9 ± 3.3 7.9 ± 4.4*      7.5 ± 5.1**,*** <0.001 
HOMA-IR‡‡, †††\ 1.3 ± 0.7 2.1 ± 1.2*      2.7 ± 2.0**,*** <0.001 
HbA1c§§ (%) 5.2 ± 0.4 5.7 ± 0.5*      7.7 ± 1.6**,*** <0.001 
Total cholesterol (mg/dl) 189.6 ± 33.9 203.5 ± 36.4*  201.2 ± 39.2** <0.001 
Triglyceride†††\ (mg/dl ) 131.6 ± 84.5 174.0 ± 115.2*      200.1 ± 130.3**,*** <0.001 
HDL-cholesterol (mg/dl ) 57.1 ± 13.0 54.7 ± 12.3*      50.6 ± 11.5**,*** <0.001 
LDL-cholesterol (mg/dl ) 107.1 ± 29.2 118.2 ± 32.4*   115.3 ± 34.4** <0.001 
AST (IU/L) 26.0 ± 7.8*† 29.3 ± 10.0*   28.6 ± 12.0** 0.003 
ALT (IU/L) 25.4 ± 12.9*† 31.8 ± 16.1*   33.1 ± 17.3** 0.039 
r-GT (IU/L) 32.5 ± 64.8*† 52.0 ± 58.8*   53.4 ± 80.6** 0.265 
WBC (x 103/ul) 6.5 ± 1.8 6.8 ± 1.8*      7.6 ± 2.2**,*** <0.001 
hs-CRP¶¶, †††\ (mg/dl) 0.17 ± 0.45 0.21 ± 0.59*      0.30 ± 0.85**,*** <0.001 
 
Data are shown as means ± the standard deviation.  
†fasting blood sugar (FBS) <100 mg/dL, ‡100≤FBS<126 mg/dL, §FBS≥126 mg/dL or taken anti-diabetic agents, ¶body mass index, ††hyper-
tension, ‡‡homeostasis model assessment of insulin resistance, §§hemoglobin A1c, ¶¶high sensitivity C-reactive protein, †††\values have been 
analyses after log-transformation 
*NG versus IFG: p<0.05, **NG versus DM: p<0.05, ***IFG versus DM: p<0.05. 
Fibrosis score=-1.675 + 0.037 x age (years) + 0.094 x BMI (kg/m2) + 1.13 x IFG/diabetes (yes = 1, no = 0) + 0.99 x AST/ALT ratio - 0.013 
x platelet (x109/l) - 0.66 x albumin (g/dl).  
16 Obesity, fatty liver and diabetes 
WHO criteria.15 Waist circumference was measured 
midway between the lowest rib and the iliac crest with 
subjects in the standing position. The percent body fat 
was determined using bioelectrical impedance analysis 
(InBody 720, Biospace Co., Seoul, Korea). An abdominal 
ultrasonography was conducted to assess the presence and 
severity of NAFLD. The same operator who was blinded 
to the medical histories and laboratory results of the par-
ticipants performed all of the ultrasounds. Fatty liver was 
diagnosed on ultrasound when there is a diffuse increased 
echogenicity of the liver texture compared to the right 
kidney. The ultrasounds were performed with a high reso-
lution B-mode scanner (EnVisor HD, version C.0.1, USA). 
Blood samples collected after overnight fasting (>12 
hours), and were analyzed for fasting glucose, lipid me-
tabolites indices such as total cholesterol, triglyceride, 
HDL-cholesterol, LDL-cholesterol (ADVIA 1650, Sie-
mens, Tarrytown, NY, USA), and hemoglobin A1c 
(HbA1c) (HLC-723GHb, TOSOH, Siba, Minaoto-ku, 
Japan). We measured high-sensitive C-reactive protein as 
a marker of systemic low-grade inflammation, which was 
measured by turbidmetric immunoassay using a Hitachi 
7170 S (Hitachi Hi-Tech, Tokyo, Japan). Additionally, 
insulin was measured by chemiluminescence using Advia 
Centaur XP (Siemens Healthcare Diagnostics, Los Ange-
les, CA, USA) and, as a marker of insulin resistance, ho-
meostasis model assessment of insulin resistance 
(HOMA-IR) index [(Insulin (μIU/ml) × Fasting glucose 
(mg/dl)/18)/22.5]) was calculated.  
 
Statistical analyses 
Data are presented as mean±SD. Variables such as fasting 
insulin, HOMA-IR, triglyceride, and hs-CRP were loga-
rithmically transformed prior to statistical analyses to 
approximate a normal distribution. Clinical characteristics 
were compared among the three groups using one-way 
analysis of variance. Prevalence of NAFLD in both non-
obese and obese people according to DM categories was 
calculated with chi-square test. After adjusting for age, 
gender and waist circumference, an analysis of covari-
ance was used to seek differences in adiposity indices, 
glucose metabolism-related parameters, liver functions, 
and fibrosis score among BMI-NAFLD categories. A 
logistic regression analysis for DM or DM plus IFG was 
performed to determine the associations with combina-
tions of BMI categories plus NAFLD grades after ad-
justment of potential confounders. Significance was de-
fined at the 0.05 level of confidence. All calculations 
were performed using the SPSS software, version 15.0 
(SPSS, Chicago, IL, USA). 
 
RESULTS 
Baseline characteristics of the subjects 
Clinical and metabolic characteristics of the subjects are 
presented in Table 1. Statistic significances were found in 
age, gender, BMI, waist circumference, body fat, blood 
pressure, alcohol, exercise, hypertension, grade of fatty 
liver, fibrosis score, glucose indices, lipid profiles, AST, 
ALT, WBC and hs-CRP between normal glucose, IFG, 
and DM group. Current smoking and r-GT were not sig-
nificantly different between 3 groups. 
 
Prevalence of NAFLD in both non-obese and obese 
people according to DM categories 
Overall prevalence of NAFLD in the present study was 
38.2% and the prevalences of NAFLD in subjects with 
normal glucose, IFG, and DM were 31.7%, 61.6%, and 
70.5%. In both obese and non-obese subjects, prevalence 
of NAFLD increased according to DM categories. Preva-
lence of NAFLD was lowest in the non-obese group with 
normal glucose (18.4%), highest in the obese group with 
diabetes (87.9%). (Figure 1) 
 
Associations between BMI-NAFLD categories and glu-
cose metabolism 
Having either obesity or not, subjects with NAFLD have 
higher glucose indices, liver enzyme levels, and fibrosis 
scores than non-obese subjects without NAFLD. And 
non-obese subjects with moderate or severe NAFLD also 
have higher glucose indices than obese subjects without 
NAFLD. In each obesity or non-obesity group, all vari-
ables show an increasing tendency according to the sever-
ity of NAFLD (Table 2). 
After adjustment of age, gender, waist circumference, 
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Figure 1. Prevalence of NAFLD in subjects with normal glucose (NG), impaired fasting glucose (IFG), and diabets mellitus (DM) accord-
ing to obesity. NG: fasting blood sugar (FBS) <100 mg/dL, IFG: 100≤FBS<126 mg/dL, DM: FBS≥126 mg/dL or taken anti-diabetic 
agents. 
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smoking status, alcohol drinking, regular exercise, the 
odds ratios (95% confidence interval) for DM were 1.00 
(0.59-1.73) in obese participants without NAFLD, 1.72 
(1.13-2.62) in non-obese participants with mild NALFD, 
5.53 (3.62-8.46) in non-obese participants with moderate 
or severe NALFD, 1.91 (1.18-3.07) in obese participants 
with mild NALFD and 4.45 (2.83-6.99) in obese partici-
pants with moderate or severe NALFD compared with 
non-obese individuals without NALFD. And odds ratios 
(95% confidence interval) for DM+IFG were 1.16 (0.85-
1.57) in obese participants without NAFLD, 1.91 (1.47-
2.46) in non-obese participants with mild NALFD, 4.39 
(3.23-5.97) in non-obese participants with moderate or 
severe NALFD, 2.10 (1.57-2.81) in obese participants 
with mild NALFD and 3.80 (2.83-5.09) in obese partici-
pants with moderate or severe NALFD compared with 
non-obese individuals without NALFD (Table 3). 
 
DISCUSSION 
The number of patients with DM have increased world-
wide.10 In order to prevent the development of DM, med-
ical interventions such as metformin or life style change 
have been studied.16,17 WHO proposed two approaches 
for the prevention of DM. One is preventing obesity in 
general population, and the other is preventing and delay-
ing the development of DM in high-risk groups.18 There-
fore, it is important to find patients at high-risk of DM 
and manage their changeable risk factors. 
In a study among healthy Japanese adults, the preva-
lence of NAFLD was 27% in subjects with normal glu-
cose and 43% in those with impaired fasting glucose and 
62% in subjects with diabetes.19 In our study, overall pre-
valence of NAFLD in the present study was 38.2% and 
prevalence of NAFLD in subjects with normal glucose, 
impaired fasting glucose, and DM were 31.7%, 61.6%, 
and 70.5%. Although the prevalence of NAFLD in obese 
subjects was higher than in non-obese subjects, preva-
lence of NAFLD in both obese and non-obese subjects 
increased according to DM categories. 
There have been many studies about the relationship 
between obesity and DM.20-22 and NAFLD is well known 
to be associated with DM and insulin resistance.23-29 Most 
Table 2. Adiposity indices and glucose metabolism related variables according to BMI-NAFLD categories 
 
OB†(-),FL‡(-) OB (-),mild FL OB(-),>mod FL OB(+), FL (-) OB(+),mild FL OB(+),>mod FLVariables 
n=2568 n=509 n=239 n=572 n=578 n=617 
p-
value
Adiposity indices        
BMI§ (kg/m2) 21.69±1.96 23.18±1.41* 23.55±1.17* 26.64±1.56*,**,*** 27.18±1.87*,**,*** 27.84±2.20*,**,*** <0.001
Abdominal fat (%) 23.99±6.06 24.63±5.67* 24.40±4.96* 29.75±6.30*,**,*** 29.62±6.56*,**,*** 29.67±6.14*,**,***§ <0.001
Glucose indices        
Fasting glucose 
(mg/dl) 88.72±16.67 95.21±18.66* 108.38±35.71*,** 90.86±13.99**,***  95.94±19.75****§  104.83±29.65*,**§
∥ <0.001
Fasting insu-
lin‡‡(uIU/L) 4.89±2.54 5.85±2.82* 7.70±3.81*,** 6.60±3.30*,***     7.97±4.05*,**,***§ 9.72±4.81
*,**§∥ <0.001
HOMA-IR¶, ‡‡ 1.08±0.63 1.38±0.76* 2.04±1.20*,**   1.50±0.92*,**,***    1.91±1.11*,**,***§ 2.52±1.50*,**§∥ <0.001
HbA1c†† (%) 5.27±0.68 5.52±0.79* 6.01±1.49*,** 5.36±0.59**,***  5.56±0.75*,***§ 5.85±1.10*†‡§∥ <0.001
Liver function test        
AST 24.77±6.96 27.68±9.29* 30.15±10.73*,** 25.09±6.38**,*** 27.49±8.03*,***§ 32.45±11.53*,**,***§∥ <0.001
ALT 21.58±9.88 28.10±12.43* 36.12±16.21*,** 25.30±10.79**,***    30.85±12.86 *,***§ 41.06±18.59*,**,***§∥ <0.001
r-GT  25.27±68.36 46.22±66.87* 56.26±83.73*  2.03±32.23**,***   45.65±43.66*,***§ 63.00±73.79*,**§∥ <0.001
Fibrosis score -3.19±1.07 -3.06±1.18* -2.96±1.27* -2.85±1.15*,**,***   -2.73±1.20*,**,*** -2.57±1.30*,**,***§∥ <0.001
 
P-values were calculated by the ANCOVA model, adjusted for age, gender and waist circumference. Data are shown as mean ± standard 
error.  
†obesity, ‡non-alcoholic fatty liver disease, §body mass index, ¶homeostasis model assessment of insulin resistance, ††hemoglobin A1c, 
‡‡values have been analyses after log-transformation 
*p<0.05 vs. OB(-), FL(-),** p<0.05 vs. OB(-),mild FL, ***p<0.05 vs OB(-),>moderate FL, § p<0.05 vs  OB(+), FL(-) , ∥p<0.05 vs OB(+), 
mild FL. 
 
 
 
Table 3. Logistic regression analysis for DM or DM plus IFG 
 
DM†, OR (95% CI) DM + IFG‡, OR (95% CI) Dependant variable Prevalence Crude Adjusted Prevalence Crude Adjusted 
OB§(-), FL¶(-) 3.04 1 1 10.48 1 1 
OB (-), mild 7.47 2.58 (1.73-3.84) 1.72 (1.13-2.62) 24.75 2.81 (2.22-3.57) 1.91 (1.47-2.46)
OB (-),>mod 19.67 7.82 (5.29-11.55) 5.53 (3.62-8.46) 43.10 6.47 (4.87-8.61) 4.39 (3.23-5.97)
OB (+), FL(-) 3.67 1.23 (0.75-1.99) 1.00 (0.59-1.73) 15.56 1.58 (1.22-2.04) 1.16 (0.85-1.57)
OB (+), mild 7.79 2.70 (1.85-3.94) 1.91 (1.18-3.07) 27.85 3.30 (2.64-4.12) 2.10 (1.57-2.81)
OB (+),>mod 17.34 6.70 (4.93-9.10) 4.45 (2.83-6.99) 42.63 6.35 (5.18-7.78) 3.80 (2.83-5.09)
 
Adjusted by age, gender, waist circumference, smoking status, alcohol drinking, regular exercise. Prevalence is shown as %.  
†fasting blood sugar (FBS) ≥126 mg/dL or taking anti-diabetic agents, ‡100≤FBS<126 mg/dL, §obesity, ¶non-alcoholic fatty liver disease 
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studies mentioned obesity explaining relationship of 
NAFLD and DM and insulin resistance. But, DM is not 
always found in obese person. 
In our study, subjects with NAFLD had higher in all 
glucose intolerance indexes (fasting glucose, fasting insu-
lin, HOMA-IR, HbA1c) than non-obese subjects without 
NAFLD regardless of obesity. It is of interest that non-
obese subjects with moderate or severe NAFLD also had 
higher in all glucose intolerance indexes than obese sub-
jects without NAFLD. Similarly, fasting glucose and 
HbA1c of non-obese subjects with mild NAFLD were 
higher than those of obese subjects without NAFLD. In 
addition, odd ratios for DM or DM plus IFG of subjects 
with mild NAFLD regardless of obesity were almost 2- 
fold compared to non-obese subjects without NAFLD. 
Moreover, the odd ratios of subjects with moderate or 
severe NAFLD regardless of obesity were almost 4- fold 
compared to non-obese subjects without NAFLD. How-
ever, this relationship was not found in obese subjects 
without NAFLD. 
Insulin, the most important hormone in diabetes, pro-
motes glucose disposal in adipose tissue and muscle and 
prevents glucose production by inhibition of glyco-
genolysis and gluconeogenesis in the liver, one of the 
insulin-sensitive tissues in the human body.30 A defect in 
insulin suppression of glucose production is found in fatty 
liver9 and then glucose production increases as a conse-
quence of increased hepatic gluconeogenesis.31 
There were several limitations in this study. It was not 
possible to determine if NAFLD itself regardless of obe-
sity plays a causal role in the development of DM be-
cause of the cross-sectional nature of this study. In this 
study, NAFLD was diagnosed through the abdominal 
ultrasonography. Although sensitivity is reduced when 
hepatic fat infiltration upon liver biopsy is less than 33%, 
ultrasonography has a sensitivity of 90% and a specificity 
of 95% in detecting moderate and severe steatosis.32 
There were several confounders affecting to NAFLD in 
this study, including liver disease and alcohol consump-
tion. We excluded subjects who had liver disease such as 
viral and alcoholic origin and used statistical analysis 
after adjusting for lifestyle factors such as smoking, alco-
hol habit and exercise. This was done to lower the possi-
bility of residual confounding effects. 
Clinically, these fatty liver and obesity are all readily 
measured and are usually used as a part of routine health 
check-up programs in Korea. Our data may suggest that 
liver ultrasonography may be a better screening tool than 
the BMI for detecting high-risk group of DM in general 
population and is a non-invasive procedure. Nowadays 
attention is focused on the prevention, earlier diagnosis 
and more aggressive control of DM in high-risk groups. 
Therefore, clinicians and investigators need to pay atten-
tion to non-obese patients with fatty liver. 
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韓國成年人身體質量指數及非酒精性脂肪肝與糖尿病的
相關性 
 
本研究調查韓國成年人在不同身體質量指數下合併非酒精性脂肪肝 (NAFLD)與
糖尿病之間的關係。研究對象為年齡 20 歲或以上，在健康促進中心有就診紀錄
者，共 5665 位。進一步排除 582 位患有病毒性或酒精性肝臟疾病者。將研究對
象分成四組，分別為未患 NAFLD 且非肥胖者(BMI<25 kg/m2) (n=2568)、未患
NAFLD 但肥胖者(BMI≥25 kg/m2) (n=572) 、患 NAFLD 但非肥胖者(n=748)、患
NAFLD 且肥胖者(n=1195)。結果發現在肥胖 並患有糖尿病者，其 NAFLD 盛行
率最高 (87.9%)。而在非肥胖且未患糖尿病者，其 NAFLD盛行率最低 (18.4%)。
在校正年齡、性別、腰圍、抽菸、飲酒、運動後，患有輕微 NAFLD 者，不論是
否肥胖，發生糖尿病或糖尿病及空腹血糖偏高情形的勝算比，為未患 NAFLD 且
非肥胖者者的兩倍。再者，不論是否肥胖，患有中度或嚴重的 NAFLD者，其發
生糖尿病的勝算比為未患 NAFLD且非肥胖者的四倍。因此，臨床醫師及研究者
應更加注意正常體位但患有脂肪肝者。 
 
關鍵字：脂肪肝、葡萄糖代謝、糖尿病、身體質量指數、肥胖 
